Business · 19/11/20261 min read
Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer
Summary
Data Presented at the 2026 EORTC-NCI-AACR Symposium Show TROP2 Levels May Help Predict Which Tumors Respond to Reqorsa® and Modulating TROP2 May Enhance Efficacy AUSTIN, Texas, Nov. 19, 2026 — Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...